Payment overview · 2025
General Payments
$5,918.69
115 reported records · 28 companies
Healthcare provider profile · identity verified
Joseph Imsais, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · AUSTIN, TX · NPI 1902096555
Verified facts
What the public records show
CMS Open Payments records show Joseph Imsais, M.D. received $5,918.69 in general payments during 2025 across 115 reported records.
Endologix LLC accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 571 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 571 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $1,288.58 | 21.8% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,056.91 | 17.9% | 11 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $757.28 | 12.8% | 6 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $424.73 | 7.2% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $264.93 | 4.5% | 14 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $262.11 | 4.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $256.30 | 4.3% | 18 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $230.95 | 3.9% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $189.86 | 3.2% | 9 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $166.34 | 2.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.35 | 1.9% | 6 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $113.50 | 1.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $89.20 | 1.5% | 2 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $84.33 | 1.4% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $73.93 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.39 | 1.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.93 | 1.1% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $59.96 | 1.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.69 | 0.9% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$50.12 | 0.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.52 | 0.8% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.96 | 0.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.78 | 0.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.33 | 0.5% | 2 | 2025 |
| Koya Medical, Inc. | Unresolved — no canonical attribution shown | $30.05 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.80 | 0.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.96 | 0.3% | 1 | 2025 |
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $15.90 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,898.47 | 114 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $989.00 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $989.00 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $757.28 | 6 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $578.06 | 7 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $415.00 | 3 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $299.58 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $294.52 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $264.93 | 14 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $262.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $256.30 | 18 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $189.86 | 9 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $165.28 | 3 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $153.77 | 1 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $116.40 | 3 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $113.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $98.25 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $89.20 | 2 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $84.33 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $73.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.39 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.93 | 4 | 2025 |
Source payment records
|
|||||
| ZILVER VENA Normalized: zilver vena |
Device | Cook Medical LLC | $63.86 | 3 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $63.85 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $50.12 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $44.52 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $40.96 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $30.26 | 1 | 2025 |
Source payment records
|
|||||
| DAYSPRING Normalized: dayspring |
Device | Koya Medical, Inc. | $30.05 | 1 | 2025 |
Source payment records
|
|||||
| KOYA MEDICAL Normalized: koya medical |
Device | Koya Medical, Inc. | $30.05 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Bolton Medical Inc | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $13.32 | 1 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $1.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 571 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 217 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 57 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
571 | 154 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
571 | 154 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 952 | 303 |
| Atorvastatin Calcium | Atorvastatin Calcium | 842 | 265 |
| Ezetimibe | Ezetimibe | 669 | 218 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 614 | 196 |
| Eliquis | Apixaban | 571 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 462 | 149 |
| Losartan Potassium | Losartan Potassium | 458 | 148 |
| Carvedilol | Carvedilol | 384 | 123 |
| Furosemide | Furosemide | 382 | 137 |
| Clopidogrel | Clopidogrel Bisulfate | 339 | 116 |
| Repatha Sureclick | Evolocumab | 263 | 52 |
| Potassium Chloride | Potassium Chloride | 252 | 90 |
| Lisinopril | Lisinopril | 225 | 79 |
| Jardiance | Empagliflozin | 217 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 70 |
| Torsemide | Torsemide | 174 | 61 |
| Xarelto | Rivaroxaban | 147 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 47 |
| Spironolactone | Spironolactone | 125 | 41 |
| Nitroglycerin | Nitroglycerin | 107 | 56 |
| Simvastatin | Simvastatin | 107 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 30 |
| Prasugrel Hcl | Prasugrel Hcl | 96 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 32 |
| Valsartan | Valsartan | 96 | 28 |
| Nifedipine Er | Nifedipine | 90 | 25 |
| Flecainide Acetate | Flecainide Acetate | 87 | 29 |
| Nebivolol Hcl | Nebivolol Hcl | 82 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 29 |
| Multaq | Dronedarone Hcl | 68 | 14 |
| Entresto | Sacubitril/Valsartan | 65 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 17 |
| Farxiga | Dapagliflozin Propanediol | 42 | 12 |
| Atenolol | Atenolol | 40 | 14 |
| Brilinta | Ticagrelor | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 12 |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | 11 |
| Klor-Con M20 | Potassium Chloride | 30 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | 11 |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,918.69 · 115 records | Endologix LLC | AREXVY, AURYON LASER SYSTEM 100-120 VAC, Alto Abdominal Stent Graft System, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CARTO 3, DAYSPRING, EDARBI, ELIQUIS, ENDOCROSS Device, FARXIGA, GLIDESHEATH SLENDER, GUIDELINER, INSPIRE, IRRISEPT, Indigo System, JARDIANCE, JOT DX, KOYA MEDICAL, Kerendia, LEQVIO, LifeVest, ONPATTRO, Ozempic, PRODIGY CATHETER, Penumbra System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, REPATHA, ROSEN, RUBY Coil, SHINGRIX, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, VENASEAL, VYNDAQEL, Varithena Administration Pack, WATCHMAN FLX, ZILVER PTX, ZILVER VENA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error